RXi forms microRNA research agreements with miRagen, Mirna

04/13/2010 | Mass High Tech (Boston)

RXi Pharmaceuticals agreed to collaborate with miRagen Therapeutics, which develops microRNA-based drugs for cardiovascular and muscular disorders, to discover pharmaceutical targets using microRNA technology. The company also will work with Mirna Therapeutics, a Texas company that focuses on early-stage drugs for cancer.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ